Learn More
PURPOSE The purpose of this study was to assess the overall burden of pancreatic cancer in Europe, with a focus on survival time in a real-world setting, and the overall healthy life lost to the disease. METHODS Real-world data were retrieved from peer-reviewed, observational studies identified by an electronic search. We performed two de novo analyses: a(More)
• It has been 15 years since the introduction of orphan medicinal product (OMP) legislation in the EU. Until 2014, one hundred and twelve orphan drugs had been approved in Europe1. • Orphan drugs represent a particular challenge to payers due to the large unmet patient need, paucity of disease information and high per-patient costs2. As of yet, there is no(More)
  • 1